<DOC>
	<DOCNO>NCT00008047</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Randomized phase I/II trial study effectiveness combination chemotherapy without paclitaxel combine radiation therapy treat patient stage II stage III cancer esophagus .</brief_summary>
	<brief_title>Combination Chemotherapy Combined With Radiation Therapy Treating Patients Who Have Stage II Stage III Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy concurrent radiotherapy fluorouracil hydroxyurea without paclitaxel term survival without dysphagia patient inoperable stage II III epidermoid carcinoma esophagus . - Compare overall survival , response rate , toxicity , quality life patient population treat regimen . OUTLINE : This randomize , open label , multicenter study . Patients stratify accord weight loss ( le 10 % v least 10 % ) inoperability criterion ( nonresectable v due anatomical terrain ) . Patients randomize one two treatment arm . - Arm I : Patients receive fluorouracil IV continuously , oral hydroxyurea , concurrent radiotherapy daily day 1-5 . - Arm II : Patients receive fluorouracil , hydroxyurea radiotherapy arm I . Patients also receive paclitaxel IV day 1 . Treatment continue every 2 week 4 course absence disease progression unacceptable toxicity . Patients possible resectable disease undergo surgical resection 4-6 week follow last course chemoradiotherapy . Patients continue unresectable disease receive 2 additional course chemoradiotherapy within 8-17 day follow last course chemoradiotherapy . Quality life assess baseline , monthly therapy , every 2 month 6 month , every 4 month 1 year , every 6 month thereafter . Patients follow every 2 month 6 month , every 4 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A maximum 90 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II ( T2 T3 , N0 , M0 ) III ( T3 , N1 , M0 ) epidermoid carcinoma esophagus Inoperable due initial extension inoperable extension No visceral metastases No extension tracheobronchial pathway No tracheoesophageal fistula No bronchoesophageal fistula No suspected respiratory mucosal involvement bronchoscopy No carcinoma situ PATIENT CHARACTERISTICS : Age : 18 80 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 120,000/mm^3 Hemoglobin least 10 g/dL Neutrophil count least 1,500/mm^3 Lymphocyte count least 1,000/mm^3 Hepatic : SGOT SGPT great 2 time normal Albumin least 3.0 g/dL Renal : Creatinine great 1.4 mg/dL Calcium le 11.2 mg/dL Pulmonary : See Disease Characteristics No severe respiratory illness ( e.g. , severe bronchopathway obstruction insufficient respiration ) No uncontrolled bronchopulmonary infection Other : No prior history malignancy except curatively treat carcinoma situ colon skin cancer No contraindication fluorouracil Not pregnant nursing Fertile patient must use effective contraception No psychiatric illness HIV negative Total protein least 65 % normal PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior endocrine therapy Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics Other : No concurrent participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>